Today: 9 June 2026
Palantir stock week ahead: Pentagon’s AI supplier crackdown puts PLTR in the crosshairs

Palantir stock week ahead: Pentagon’s AI supplier crackdown puts PLTR in the crosshairs

NEW YORK, March 7, 2026, 14:54 EST

  • Palantir shares finished the day up on Friday, shaking off a session marked by choppy trading.
  • After Washington took action against AI lab Anthropic, contractors working with the Pentagon are now rethinking which models they rely on.
  • Investors are watching Wednesday’s U.S. inflation data, which could shake up rate expectations that typically steer high-multiple tech stocks.

Palantir Technologies shares finished the week higher, catching a lift after the U.S. government took aim at a major AI supplier—a move that rattled defense software supply chains. The stock settled at $157.16 on Friday.

The Pentagon tagged Anthropic as a “supply-chain risk” on Thursday, which, per Reuters, blocks government contractors from deploying its tech in U.S. military projects. Microsoft’s spokesperson told Reuters that after a legal review, the company determined Anthropic’s offerings “can remain available” via Microsoft platforms for customers outside the Pentagon. Reuters

This puts Palantir in a tight spot. Its Maven Smart Systems, critical for intelligence and targeting, are built around Anthropic’s Claude code, according to Reuters. Now, PLTR investors face a fresh headline risk: key defense software might need overhaul, swaps, or government exemptions—timing unknown.

Policy got tighter again early Saturday. According to the Financial Times, cited by Reuters, the Trump administration is pushing for tough new requirements on civilian AI contracts—companies would have to permit “any lawful” use of their models. Josh Gruenbaum of the General Services Administration told Reuters it would be “irresponsible” and “dangerous” for the agency to keep working with Anthropic. GSA has dropped Anthropic’s OneGov contract. Reuters

Markets are twitchy. U.S. stocks slipped Friday, with oil surging 12% and February payrolls posting an unexpected drop—touching off fresh stagflation worries as the Fed eyes rate cuts. “It raises the question of whether the Fed will even be able to cut rates,” said Kristina Hooper, chief market strategist at Man Group. Reuters

Palantir spent Friday bouncing between $150.29 and $161.45, as traders scrambled to react to fresh defense and AI news against a backdrop of macro turbulence.

This week, traders are eyeing potential Pentagon updates on how the Anthropic designation actually plays out for contractors. Key questions: Do current systems need instant changes, or will transition plans let them keep running for now?

Inflation is on the radar too. The U.S. Labor Department drops February’s consumer price index numbers this Wednesday, March 11, at 8:30 a.m. ET—a report known to shake up Treasury yields and high-growth software stocks.

If the supplier dispute blows up into a full-blown legal battle, deployments could stall. Anthropic CEO Dario Amodei told Reuters the company got a letter flagging it as a supply-chain risk and said they “see[s] no choice but to challenge it in court.” Contractors and customers might be left grappling with rules that keep changing, not just shifting code. Reuters

Oil’s also in play. Goldman Sachs has flagged the risk of crude jumping past $100 a barrel as soon as next week if traffic through the Strait of Hormuz fails to rebound—a move that would sustain pressure on rates and send ripples through risk assets.

Palantir heads into the week riding recent gains, yet now faces a fresh worry tied to its defense tech offerings: exactly whose models power these tools, and which ones Washington will actually approve for contractor use.

Stock Market Today

  • Wheat Futures Rise as Export Inspections Show Mixed Data
    June 9, 2026, 9:19 AM EDT. Wheat futures gained on Monday, with Chicago SRW up 5-7 cents, KC HRW up 9-11 cents, and MPLS spring wheat rising slightly. Export inspections reported 319,730 MT shipped in the week ending June 4, down 20.65% from the previous week and 1.38% below last year. Mexico led exports with 83,211 MT. Managed money increased net shorts in Chicago wheat futures to 57,871 contracts, hitting a record bear move since 2006. Ukraine's wheat crop estimate rose 1.8 MMT to 21.7 MMT. July 26 CBOT Wheat futures closed at $5.86 ½, up 6 ½ cents, reflecting bullish momentum amid volatile trading conditions.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Amazon stock week ahead: What traders watch after the Amazon outage and AWS’s new healthcare AI push
Previous Story

Amazon stock week ahead: What traders watch after the Amazon outage and AWS’s new healthcare AI push

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 09.03.2026

Go toTop